$2.11 Million in Sales Expected for Abeona Therapeutics Inc (ABEO) This Quarter

Analysts expect Abeona Therapeutics Inc (NASDAQ:ABEO) to announce sales of $2.11 million for the current fiscal quarter, Zacks Investment Research reports. Four analysts have made estimates for Abeona Therapeutics’ earnings, with the lowest sales estimate coming in at $700,000.00 and the highest estimate coming in at $2.60 million. Abeona Therapeutics reported sales of $220,000.00 during the same quarter last year, which would suggest a positive year-over-year growth rate of 859.1%. The business is expected to report its next earnings report on Tuesday, August 21st.

On average, analysts expect that Abeona Therapeutics will report full year sales of $9.21 million for the current financial year, with estimates ranging from $5.70 million to $10.50 million. For the next year, analysts expect that the company will report sales of $18.95 million per share, with estimates ranging from $4.08 million to $43.20 million. Zacks’ sales averages are an average based on a survey of analysts that follow Abeona Therapeutics.

Abeona Therapeutics (NASDAQ:ABEO) last released its earnings results on Monday, May 14th. The biopharmaceutical company reported ($0.18) earnings per share for the quarter, beating the Zacks’ consensus estimate of ($0.19) by $0.01. The firm had revenue of $2.60 million for the quarter, compared to analysts’ expectations of $0.27 million. Abeona Therapeutics had a negative net margin of 939.83% and a negative return on equity of 23.57%.

A number of research analysts have weighed in on ABEO shares. Maxim Group set a $35.00 target price on shares of Abeona Therapeutics and gave the company a “buy” rating in a research note on Monday, March 19th. Cantor Fitzgerald set a $36.00 target price on shares of Abeona Therapeutics and gave the company a “buy” rating in a research note on Tuesday, March 20th. Zacks Investment Research cut shares of Abeona Therapeutics from a “hold” rating to a “sell” rating in a research note on Wednesday, March 21st. HC Wainwright set a $30.00 target price on shares of Abeona Therapeutics and gave the company a “buy” rating in a research note on Monday, April 2nd. Finally, ValuEngine upgraded shares of Abeona Therapeutics from a “sell” rating to a “hold” rating in a research note on Monday, April 2nd. Two research analysts have rated the stock with a hold rating and nine have given a buy rating to the company’s stock. Abeona Therapeutics currently has a consensus rating of “Buy” and a consensus price target of $28.56.

Abeona Therapeutics traded down $0.20, reaching $15.90, during midday trading on Monday, according to MarketBeat.com. The company had a trading volume of 850,422 shares, compared to its average volume of 1,082,414. The stock has a market cap of $749.79 million, a price-to-earnings ratio of -23.94 and a beta of 1.27. Abeona Therapeutics has a 12-month low of $4.55 and a 12-month high of $22.75.

Several hedge funds have recently made changes to their positions in the stock. Viking Global Investors LP lifted its stake in shares of Abeona Therapeutics by 80.5% during the 4th quarter. Viking Global Investors LP now owns 4,040,727 shares of the biopharmaceutical company’s stock valued at $64,046,000 after buying an additional 1,802,007 shares in the last quarter. BlackRock Inc. lifted its stake in shares of Abeona Therapeutics by 0.3% during the 1st quarter. BlackRock Inc. now owns 1,873,472 shares of the biopharmaceutical company’s stock valued at $26,884,000 after buying an additional 5,094 shares in the last quarter. Millennium Management LLC lifted its stake in shares of Abeona Therapeutics by 2,357.3% during the 1st quarter. Millennium Management LLC now owns 916,256 shares of the biopharmaceutical company’s stock valued at $13,148,000 after buying an additional 878,969 shares in the last quarter. Nexthera Capital LP purchased a new stake in shares of Abeona Therapeutics during the 1st quarter valued at approximately $5,302,000. Finally, Northern Trust Corp lifted its stake in shares of Abeona Therapeutics by 1.3% during the 1st quarter. Northern Trust Corp now owns 304,434 shares of the biopharmaceutical company’s stock valued at $4,369,000 after buying an additional 3,941 shares in the last quarter. Institutional investors own 69.11% of the company’s stock.

Abeona Therapeutics Company Profile

Abeona Therapeutics Inc, a clinical-stage biopharmaceutical company, focuses on developing and delivering gene therapy products for severe and life-threatening rare diseases. The company's lead programs are EB-101 (gene-corrected skin grafts) for recessive dystrophic epidermolysis bullosa (RDEB); ABO-102, which are AAV based gene therapies for Sanfilippo syndrome type A; and ABO-101, an adeno-associated virus (AAV) based gene therapies for Sanfilippo syndrome type B.

Get a free copy of the Zacks research report on Abeona Therapeutics (ABEO)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Abeona Therapeutics (NASDAQ:ABEO)

Receive News & Ratings for Abeona Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Abeona Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply